Chооse the cоrrect аnswer A middle-аged аdult with a 10-year history of type 2 diabetes with no current evidence of microvascular complications is treated with metformin (Glucophage) 1000 mg twice daily, exenatide extended-release (Bydureon) 2 mg subcutaneously once weekly, insulin Lantus (glargine) 34 mg subcutaneously at bedtime, and insulin aspart (Novolog) 7 units with breakfast, 5 units with dinner, and 10 units with dinner. The patient's most recently A1C was 8.1%. The patient provided the following self-reported glucose values: Date Fasting Before Lunch Before Dinner Bedtime 4/19 156 122 131 118 4/20 172 117 91 100 4/21 164 89 95 4/22 145 114 102 4/23 158 110 140 126 4/24 163 What, if any, adjustments to the diabetes treatment plan are indicated at this time?